Drug Discovery World

APRIL 14, 2023

Carl H June, MD, FAACR – Lifetime Achievement in Cancer Research June, a Fellow of the AACR Academy, is the Richard W Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.

Genetics 52

Genetics Research Medicine Clinical Research 52

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Why is it Difficult to Develop CNS Therapeutics?

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials 52

Trials Antibody In-Vitro Medicine 52

The Pharma Data

AUGUST 22, 2021

The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. The trial included 5,197 participants in a 2:1 randomisation AZD7442 to placebo. The trial was conducted in 87 sites in the US, UK, Spain, France and Belgium.

Trials 52

Trials Antibody Vaccination Vaccine 52

Delveinsight

DECEMBER 10, 2020

The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate. In a pooled analysis of 11,636 participants enrolled in two separate clinical trials in the U.K.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

MARCH 17, 2021

The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 The monarchE trial is ongoing and patients will continue to be followed to assess safety, PROs and other endpoints. had fatal outcomes.

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

NOVEMBER 18, 2020

. “Effective delivery of this treatment can be logistically complicated,” said Dr. Kami Kim , director of the Division Infectious Diseases and International Medicine at USF Health Morsani College of Medicine. ” The monoclonal antibody is a man-made protein that acts like a human antibody in the immune system. .

Antibody 40

Antibody Medicine Radiology Protein 40

The Pharma Data

APRIL 7, 2023

” These sNDAs are supported by results from the PHAROS trial (NCT03915951), an open-label, multicenter, non-randomized, Phase 2 study (n=98) to determine the safety, tolerability, and efficacy of BRAFTOVI given in combination with MEKTOVI in patients with BRAF V600E-mutant metastatic NSCLC.

FDA Approval 40

FDA Approval Drugs Medicine Genetics 40

The Pharma Data

FEBRUARY 1, 2021

1, 2021 (American Heart Association News) — Medical science has come a long way since the days of “bikini medicine,” when the only time doctors managed a woman’s health differently than a man’s was when treating the parts of her body found under a bikini. MONDAY, Feb. It’s that they age differently.

Hormones 40

Hormones Radiology Research Medicine 40

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The price of that prize is incalculable. Merck’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92